Rimonabant
In vial of 0.5 g. net
TargetMol Chemicals Inc.
Product Overview
Product / Grade Name
Rimonabant
Maker Name
Product Description
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.
Hazard Classification
UN Number
:IMGD Class
:Packing Group
:
Visual Overview
Corporate Video